Liver Fibrosis in Type 2 Diabetes and Obesity: A Case-Based Approach

·21 min·2 clips

Professor Sven Fronke reveals why fibrosis stage, not fat, decides a patient's future in liver disease.

The episode is the conclusion of a three-part docu-series titled 'Breaking the Silence, Tackling Liver Fibrosis in Metabolic-Associated Steatohepatitis (MASH)' on Medscape. Host Sharon Thomas introduces the series' focus on advances in MASH management, emphasizing that fibrosis stage, not fat or inflammation, is the strongest predictor of liver-related events and mortality. The setting shifts to Antwerp, Belgium, where Professor Sven Fronke, an expert in non-invasive testing, guides a case-based discussion on a hypothetical male patient in his early 50s with obesity and long-standing type 2 diabetes. Professor Fronke explains that adipose tissue dysfunction, particularly in visceral fat, drives insulin resistance and liver injury, with type 2 diabetes accelerating fibrosis progression. He outlines current guidelines recommending active case-finding in such patients using non-invasive tests. The assessment begins with calculating the FIB4 score, where low values indicate low risk, high values suggest high risk, and intermediate results lead to further testing like liver stiffness measurement. Professor Fronke describes using ultrasound with liver stiffness in his clinic, interpreting values above 8 kPa as indicative of significant fibrosis. He highlights the 'actionable danger zone' of F2-F3 fibrosis, where intervention can still reverse disease before progression to cirrhosis. Treatment starts with optimizing metabolic control through lifestyle changes, maximizing GLP-1 receptor agonist doses, and using statins or pioglitazone where appropriate. For patients with persistent F2-F3 fibrosis, adding resmetirom—a liver-targeted thyroid hormone receptor beta agonist approved in Europe in 2025—is discussed, with Professor Fronke noting its safety and efficacy in combination with GLP-1 receptor agonists. Monitoring involves checking liver enzymes every six months and liver stiffness annually, focusing on trends over time rather than single measurements. The episode concludes with key messages: the complex relationship between liver disease, adipose dysfunction, and diabetes; the importance of non-invasive test combinations for assessment; and the need to treat liver fibrosis as part of cardiometabolic care. Sharon Thomas summarizes the challenge of not overlooking at-risk patients and thanks the experts involved.

As heard by us

A focused guide to liver workup decisions, with a careful eye on timing and readouts.

The conversation treats MASH as part of metabolic care, not as a liver problem on its own. It follows a patient with obesity and long-standing type 2 diabetes through the questions clinicians actually have to answer: who needs noninvasive testing, when a measurement should be…

Read the full review in PlayNext →

Why you'd press play

You want a clear path through MASH fibrosis decisions.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Keeping Current